{
  "id": "cluster_4_doc3",
  "content": "Policy update effective February 1st: CAR-T therapies requiring prior auth will now be expedited for rare hematopoietic conditions. Impacts patients at 14 designated centers including Lakeside Oncology. Requires tertiary pathology review and EOC committee approval (reference: PHX-9901B).",
  "metadata": {
    "format": "policy_document"
  }
}